At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 92 enrolled
Drug / intervention
Granisetron +1 moredrug
Likely dose
Granisetron 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Using Pharmacogenomics (PGx) Results to Guide Post-operative Nausea and Vomiting (PONV) Treatment Practices: A Pilot Study
In Brief
A Phase 4 clinical trial evaluating Granisetron and Ondansetron for Postoperative Nausea. Completed, enrolled 92 participants across 1 site.
Detailed Summary
The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Nausea
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2018
Primary CompletionDec 2019
TodayJul 2026
First PostedApr 19, 2018
Enrollment StartMay 2, 2018
Primary CompletionDec 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.2 years ago
Interventions
Granisetrondrug
Rapid metabolizer will receive 1mg IV Granisetron
Ondansetrondrug
Poor or normal metabolizers will receive 4mg Ondansetron IV